Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
about
A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrAllogeneic hematopoietic cell transplantation: the state of the artClinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignanciesA phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.A disease risk index for patients undergoing allogeneic stem cell transplantation.Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphomaConditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationSalvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?Management of relapsed-refractory diffuse large B cell lymphoma.Transplantation for non-Hodgkin lymphoma.The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasPushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Chimeric antigen receptor T-cell therapies for lymphoma.Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.Guidelines for the management of diffuse large B-cell lymphoma.
P2860
Q33829105-00BB4D3A-4AD9-4EB6-ABEA-A341CF6B34DEQ34044024-A56C1D52-2B34-4011-9FC9-D9B181D724A8Q34145155-36E1AA85-6311-40E4-8052-B6F4181DCD28Q34365673-BA04A352-BB0E-4B93-86AB-3A9BA109F3ACQ35213027-7569AE3B-82C6-4096-AE90-18D0B95BD719Q35218515-C58EB180-B930-4705-BBBA-9E967A1ADDF4Q35223780-957E18DE-5B0F-40BC-B406-35B677041E68Q36035591-9ECDC7B3-F2F9-4061-A019-8F5029AC2FB5Q36141944-AE293738-2A2D-4447-A250-8842326F23DAQ36336614-33DAD69E-2FFD-40AA-9FE4-E01B0E3219F8Q36410168-DB776C92-E12D-4D3C-80D0-161CC38CBFA5Q36426327-C02AAF20-43FB-4760-BE26-64C5E2FB0024Q36570651-85D68A89-20E0-4B74-9836-329CD231C409Q36834194-D8CF27FC-DF65-4CE7-B4B4-DD0A34FD73D7Q36862464-1E90E23C-26E2-4FCB-8C8A-C1157224FD4AQ36905562-40486612-6760-4FB4-BA47-52E237621341Q37083601-5509045F-7BB6-4E5C-8AA9-FAD30B276CA8Q37375545-2B14B2CF-FAEF-4295-9B0B-12AB8080BE58Q37585103-F63C3F43-7DE2-4353-A85E-8F070DADBCA5Q37654010-4E8AFE7E-97D4-4BB5-A5E3-AE703D5D340EQ37810079-D1D41A1A-8065-41DE-AB6B-3DB372F2E54FQ37824456-55FA9761-008B-45FE-8027-BEFD1D9E430FQ37938531-62DFAC4B-0570-40E7-BD75-529B1CA068F6Q37966693-7A16650C-4231-4A0F-B18D-D254023BC257Q38074021-95EB57F6-638C-4C07-99CA-D149355A3399Q38109511-87FC23B4-7684-4363-823A-CF9CAA1F90E2Q38267567-184465CB-5EDA-4593-BE82-967CD86942EEQ38488058-32D51D6B-2CBA-4C8D-9950-94E1C7A5B2F4Q38600697-6A61D5B9-2962-4D77-84DD-ABB0F7CACAD2Q38860997-A88F5627-15ED-4C34-B219-450FE80F219BQ41088166-E71B765D-E934-4E0D-8FFE-2C1F1DA9A839Q41509697-6DF94332-D55A-4A24-92C9-51636193E4F5Q43607225-F9647A6F-A98E-48FE-A8F0-0DD78C23A73DQ44943572-5AB6874B-A82A-453C-87F2-8EC8ADD5FFC0Q47142550-6C3CCE17-43D4-47C3-BB47-CB3D4396612DQ50941578-4F4C3C23-C1C1-426B-B605-5A72BE21ED03Q53291069-4F1620A7-8231-437C-AEAC-84E4EF99E6B4Q53297754-3E7CA12C-4BA1-4ADA-91E2-70F5212B0FACQ54708579-026500F0-03E7-4965-A0D4-3A5C3E421DE5
P2860
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Non-myeloablative allogeneic h ...... homa: a multicentre experience
@en
Non-myeloablative allogeneic h ...... oma: a multicentre experience.
@nl
type
label
Non-myeloablative allogeneic h ...... homa: a multicentre experience
@en
Non-myeloablative allogeneic h ...... oma: a multicentre experience.
@nl
prefLabel
Non-myeloablative allogeneic h ...... homa: a multicentre experience
@en
Non-myeloablative allogeneic h ...... oma: a multicentre experience.
@nl
P2093
P2860
P50
P1476
Non-myeloablative allogeneic h ...... homa: a multicentre experience
@en
P2093
Andrew R Rezvani
Andrew Yeager
Benedetto Bruno
Christopher Bredeson
Edward Agura
Firoozeh Sahebi
Judith Shizuru
Lalitha Norasetthada
Michael Maris
Michelle E Bouvier
P2860
P304
P356
10.1111/J.1365-2141.2008.07365.X
P407
P577
2008-08-28T00:00:00Z